Assess drug efficacy against blood cancer progenitor cells.
We incubate diseased cells with your test compound(s) in a semi-solid, methylcellulose-based medium and we then assess cultures for changes in the number of cancer progenitor-derived colonies. We can also test your drug in a standard CFC assay to look for off-target toxicity to healthy donor progenitor cells.
Advantages:
The preclinical screening method that helps clients eliminate bad players earlier in the drug development process. White Paper
Colony Forming Cell assays can predict compound induced toxicities including neutropenia, thrombocytopenia, anemia and lymphotoxicity. Video
This in vitro assay has been validated by ECVAM (European Centre for the Validation of Alternative Methods) and correlates well with clinical neutropenia for many drug classes. Protocol
Copyright © 2024 Discovery Life Sciences. All rights reserved.
Designed & Developed by Altitude Marketing